Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Quarterly results
Appointed director
|
|
Biofrontera Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/13/2023 |
8-K
| Quarterly results |
| 10/10/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 10/04/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 10/03/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/11/2023 |
8-K
| Quarterly results |
| 07/13/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 07/12/2023 |
8-K
| Quarterly results |
| 07/03/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
| 06/02/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 06/01/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 05/26/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o... |
| 05/12/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
8-K
| Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Financial Statements and Ex... |
| 04/17/2023 |
8-K
| Quarterly results |
| 03/08/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 03/02/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 01/09/2023 |
8-K
| Quarterly results |
| 12/16/2022 |
8-K
| Appointed a new director |
| 11/08/2022 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 10/24/2022 |
8-K
| Quarterly results |
| 10/14/2022 |
8-K
| Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I... |
| 10/05/2022 |
8-K
| Quarterly results |
| 07/27/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu... |
| 07/12/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 05/24/2022 |
8-K
| Quarterly results |
| 05/20/2022 |
8-K
| Quarterly results |
| 05/13/2022 |
8-K
| Quarterly results |
| 04/08/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 04/06/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 04/05/2022 |
8-K
| Amended existing or entered into new employment agreement with an officer |
| 03/08/2022 |
8-K
| Quarterly results |
| 01/13/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 12/29/2021 |
8-K
| Quarterly results |
| 12/03/2021 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"Form of Purchaser Warrant",
"Form of Pre-Funded Warrant",
"Form of Unit Purchase Option",
"BIOFRONTERA INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of November 29, 2021, between Biofrontera Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4 of the Securities Act , and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Comp...",
"Form of Registration Rights Agreement",
"Biofrontera Inc. Pricing of $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules WOBURN, MA. November 29, 2021— Biofrontera, Inc. , today announced today that it has entered into a securities purchase agreement with a single institutional investor for the purchase of 2,857,143 shares of its common stock and warrants to purchase up to an aggregate of 2,857,143 shares of common stock, in a private placement. The combined purchase price for one share of common stock and a warrant to purchase one share of common stock is $5.25, priced at-the-market under Nasdaq rules. The warrants have an exercise price of $5.25 per share, will be immediately exercisable, and will expire five years from the issuance date.",
"Biofrontera Inc. Announces Closing of $15 Million Private Placement WOBURN, MA., December 01, 2021— Biofrontera Inc. , a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the closing of a private placement with a single institutional investor for the purchase of 2,857,143 shares of its common stock and warrants to purchase up to an aggregate of 2,857,143 shares of common stock. The combined purchase price for one share of common stock and a warrant to purchase one share of common stock was $5.25, priced at-the-market under Nasdaq rules. The warrants have an exercise price of $5.25 per share, will be immediately exercisable, and will expire five years from the issuance date." |
|
|
|
|